Search

Displaying results 4111 - 4120 of 8974 in total
  1. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    ) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background … In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body

  2. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    Up to now (July 2013), the results of this study have not yet been published. … The exact mechanism of action is still being investigated for all of the potential indications of agmatine.

  3. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. … It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

  4. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day. … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia.

  5. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  6. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. … GAA to the lysosome, where it can perform its normal function.

  7. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728] … [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.

    Categories: Approved Treatments for COVID-19
  8. Drug

    Aprobarbital

    go.drugbank.com/drugs/DB01352
    ExperimentalIllicit

    A primary treatment indicated for the use of aprobarbital was subsequently insomnia. … Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects.

  9. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  10. Drug

    Fenbufen

    go.drugbank.com/drugs/DB08981
    Approved

    It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. … Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.